Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

UTHR

$595.940.89%-5.38

United Therapeutics Corp (UTHR)

Date: O: H: L: C: Vol:

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

SGIOY vs. UTHR: Which Stock Is the Better Value Option? - Zacks Investment Research

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research

Options exercised at $117.76 a share accompanied sales by United Therapeutics (UTHR) CEO's trusts. - Stock Titan

$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga

United Therapeutics Rising Ahead of Next Earnings Report - FXEmpire

FDA clears United Therapeutics to begin Treprostinil-Iloprost trial - StreetInsider

CEO trusts exercised $117.76 options and sold 9,500 shares in United Therapeutics (UTHR). - Stock Titan

S&P 500 Futures Up in Premarket Trading; MSG Sports, United Therapeutics Lag - Barron's

United Therapeutics CEO sells $5.5M in stock By Investing.com - Investing.com Nigeria

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 23 October - Investing.com Nigeria

United Therapeutics CEO sells $5.5M in stock - Investing.com

After exercising options at $117.76, United Therapeutics (UTHR) CEO trusts sell 9,500 shares. - Stock Titan

United Therapeutics (NDQ:UNTR): The Only Company Attempting Xenotransplantation At Scale! - Stocks Down Under

U.S. transgender billionaire Martine Rothblatt sells $5.5 million in United Therapeutics stock - Billionaires.Africa

Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock - Investing.com

United Therapeutics Gets FDA Clearance to Start Phase 2 SUMMIT Trial of Treprostinil Soft Mist Inhaler in PH-COPD - BioBuzz

United Therapeutics to build a $9 million hangar at Rochester's airport - Post Bulletin

United Therapeutics CEO Rothblatt sells $5.3m in UTHR stock - Investing.com

Is United Therapeutics Corp (UTHR) Overvalued After 3.8% Rally? - GuruFocus

Generation Park lands new facility to scale xeno-organ production - InnovationMap

United Therapeutics authorizes $2 billion buyback program - Investing.com

United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance

United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com

CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria

United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com

United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance

United Therapeutics opens third xenograft production facility - Investing.com

A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan

United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance

United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria

After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga

United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus

Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan

United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill

United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com

Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com

After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan

United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria

After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan

A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research

Ähnlich wie UTHR

VTRS$19.060.71%

NBIX$165.850.60%

ELAN$25.212.58%